An observational study in Robotic, Laparoscopic and Anterior Resection for Rectal Cancer, sponsored by Daorong Wang. Completed at 1 site in China. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by Daorong Wang · Observational
This retrospective study collected participants who underwent robotic or laparoscopic anterior resection for rectal cancer at the North People's Hospital in Jiangsu from January 2019 to January 2023.
Daorong Wang is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants who underwent robotic or laparoscopic anterior resection for rectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The criteria include: (1) pathology of low rectal cancer (within 10 cm from the anal margin); (2) access to comprehensive pathological and computed tomography (CT) data; (3) completeness of clinical data.
Exclusion Criteria:
patients with other malignant tumors besides rectal cancer, benign disease surgery, and emergency surgery.
Procedure: robotic surgery · Procedure: laparoscopic surgery
Procedure: robotic surgery · Procedure: laparoscopic surgery
robotic surgery
laparoscopic surgery
postoperative recurrence rate
postoperative recurrence rate
Time frame: 2018-2024
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daorong Wang